Title:
ＴＥＡＣおよびＡＴＴＡＣ腫瘍免疫学的組成物および方法
Document Type and Number:
Japanese Patent JP2022530685
Kind Code:
A
Abstract:
本開示は、がんの標的化のための標的化されたＴ細胞誘導剤（ＴＥＡＣ）および抗体腫瘍標的化アセンブリー複合体（ＡＴＴＡＣ）を提供する。本明細書に記載のＴＥＡＣまたはＡＴＴＡＣは、例えば、より長い半減期を有してもよく、または単剤中に複数の成分を含んでもよい。
Inventors:
Kobold,mark
Prior, Martin
Corsart, Allison
Prior, Martin
Corsart, Allison
Application Number:
JP2021565716A
Publication Date:
June 30, 2022
Filing Date:
April 23, 2020
Export Citation:
Assignee:
The General Hospital Corporation
Levitope Limited
Levitope Limited
International Classes:
A61K39/395; A61K31/7088; A61K38/20; A61K45/00; A61K47/60; A61K47/64; A61K47/68; A61P35/00; A61P35/02; C07K16/28; C07K16/30; C07K16/46; C07K19/00; C12N15/115; C12N15/12; C12N15/13; C12N15/62
Attorney, Agent or Firm:
Hiroshi Kobayashi
Norio Omori
Maruyama Tomohiro
Norio Omori
Maruyama Tomohiro
Previous Patent: Circuit breaker
Next Patent: Diffraction light guide plate and manufacturing method of diffraction light guide plate
Next Patent: Diffraction light guide plate and manufacturing method of diffraction light guide plate